Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 10/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059117 | 0.74 | CA9 (0.40) | CA12CA9CA1CA2 | |
| SCHEMBL5475893 | 0.70 | CA9 (0.42) | CA12CA9CA1CA2BACE1 | |
| SCHEMBL18529414 | 0.68 | BACE1 (0.36) | CA9BACE1BACE2KDM4ENSD2 | |
| SCHEMBL14625877 | 0.67 | CA9 (0.50) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL1950126 | 0.66 | PRKCI (0.35) | BACE1KDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL11997372 | 0.66 | ALDH1A1 (0.39) | KDM4ENSD2ALDH1A1MAPTBRPF1 | |
| SCHEMBL25609811 | 0.63 | CA9 (0.58) | CA12CA9CA1CA2NSD2 | |
| SCHEMBL9245703 | 0.63 | MAOA (0.51) | CA12CA9CA1CA2KDM4E | |
| SCHEMBL2881312 | 0.62 | CASP1 (0.35) | CA1CA2BACE1KDM4EALDH1A1 | |
| SCHEMBL1950822 | 0.61 | MAPT (0.35) | CA9KDM4EALDH1A1MAPTPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1773828-A1 | HETEROCYCLE -SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010642-A1 | HETEROCYCLE-SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | CA12 4622/4885CA9 3416/4885CA1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.